Even injection users find tablets appealing More than two thirds ( 71.88% ) of previous GLP-1 injection users said a daily tablet feels more appealing than a weekly injection, while 66.67% of current injection users agreed, showing strong interest in oral options even among experienced users
Gastrointestinal adverse events were the most common, and treatment discontinuations increased with higher doses, reinforcing the importance of careful patient selection and shared decision-making
The OASIS 4 clinical trial published in the New England Journal of Medicine in 2025 followed adults with overweight or obesity for 71 weeks
Keywords: Psoriasis, hidradenitis suppurativa, Hailey-Hailey disease, medical dermatology, immunology, acanthosis nigricans Introduction Glucagon-like peptide-1 (GLP-1) agonists are a class of medications that mimic GLP-1, a hormone which belongs to the incretin family
Women and adults aged 66 to 75 saw the most significant decrease in obesity.In Florida, a series of actions in 2024 chipped away the obesity rate: sales of weight-loss medications soared, new paths to getting the drugs opened, and the state-imposed prescribing requirements helped to ensure successful outcomes.There are currently three medications (GLP-1s) on the market that the FDA has specifically approved to treat obesity Wegovy, Zepbound, or Saxenda
